

## **CoAxia Receives \$17.6 Million in Series B Funding**

*Ischemic Stroke Device Company to Fund Development and Clinical Testing of Company's Stroke Treatment With Latest Capital Infusion*

Maple Grove, MN - October 13, 2004 - CoAxia, Inc., a development-stage medical device company in clinical testing of a catheter-based treatment for ischemic stroke, announced today it has closed \$17.6 million in Series B financing. New investors include Prism Venture Partners and Canaan Venture Partners, which co-led the round, and Baird Venture Partners.

"CoAxia is very pleased to have raised this additional capital to fund further development and clinical testing of our NeuroFlo™ catheter system in patients with cerebral ischemia, notably in those with ischemic stroke and cerebral vasospasm," said president and CEO, Andrew M. Weiss. "We believe this funding will allow us to continue development of our technology and significantly advance clinical testing. We are encouraged that leading investors such as Canaan Venture Partners, Prism Venture Partners, Affinity Capital, J&J Development Corporation and Baird Venture Partners chose to participate in this financing round."

Cerebral ischemia, including ischemic stroke, is a condition that annually afflicts and debilitates millions of people worldwide. CoAxia's NeuroFlo catheter system is designed to enhance blood flow to the brain following a cerebral ischemic event, to provide a safe and effective treatment and improve patient outcomes.

### **About CoAxia, Inc.**

CoAxia, Inc., a Maple Grove, MN-based, privately held, development-stage medical device company, is pioneering the use of catheter-based perfusion augmentation systems for the treatment of cerebral ischemia. Cerebral ischemia is characterized by a reduction in blood flow to the cerebral vasculature and includes ischemic stroke and vasospasm, which effect millions of people worldwide. CoAxia currently has CE marked and FDA cleared catheters for controlling flow in the peripheral vasculature. The company is developing and testing its proprietary technology platform, NeuroFlo™, which redistributes blood flow to the brain during acute cerebral ischemic events such as stroke or vasospasm.